Literature DB >> 15031723

Specific downregulation of bcl-2 and xIAP by RNAi enhances the effects of chemotherapeutic agents in MCF-7 human breast cancer cells.

Raquel T Lima1, Luís M Martins, José E Guimarães, Clara Sambade, M Helena Vasconcelos.   

Abstract

Antiapoptotic genes such as bcl-2 or xIAP may be responsible for resistance to apoptosis induced by cytotoxic drugs. The aim of this study was to investigate if downregulation of bcl-2 or xIAP by RNA interference (RNAi) would sensitize MCF-7 cells to etoposide and doxorubicin. FITC-siRNAs uptake was verified by fluorescence microscopy and downregulation of Bcl-2 or XIAP was confirmed by Western Blotting. Both siRNAs reduced the number of viable cells and increased cellular apoptosis. Treatment with siRNAs followed by treatment with etoposide or doxorubicin further reduced the number of viable cells, when compared to either of the treatments alone. Therefore, downregulation of bcl-2 or xIAP by RNAi enhances the effects of etoposide and doxorubicin.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15031723     DOI: 10.1038/sj.cgt.7700706

Source DB:  PubMed          Journal:  Cancer Gene Ther        ISSN: 0929-1903            Impact factor:   5.987


  46 in total

1.  CHIP buffers heterogeneous Bcl-2 expression levels to prevent augmentation of anticancer drug-resistant cell population.

Authors:  M Tsuchiya; Y Nakajima; T Waku; H Hiyoshi; T Morishita; R Furumai; Y Hayashi; H Kishimoto; K Kimura; J Yanagisawa
Journal:  Oncogene       Date:  2014-12-01       Impact factor: 9.867

2.  Polyamidoamine dendrimers-based nanomedicine for combination therapy with siRNA and chemotherapeutics to overcome multidrug resistance.

Authors:  Jiayi Pan; Livia P Mendes; Momei Yao; Nina Filipczak; Sumanta Garai; Ganesh A Thakur; Can Sarisozen; Vladimir P Torchilin
Journal:  Eur J Pharm Biopharm       Date:  2019-01-08       Impact factor: 5.571

Review 3.  Nanoformulations for combination or cascade anticancer therapy.

Authors:  Lei Miao; Shutao Guo; C Michael Lin; Qi Liu; Leaf Huang
Journal:  Adv Drug Deliv Rev       Date:  2017-06-15       Impact factor: 15.470

4.  Control of cell survival and proliferation by mammalian eukaryotic initiation factor 4B.

Authors:  David Shahbazian; Armen Parsyan; Emmanuel Petroulakis; Ivan Topisirovic; Yvan Martineau; Bernard F Gibbs; Yuri Svitkin; Nahum Sonenberg
Journal:  Mol Cell Biol       Date:  2010-01-19       Impact factor: 4.272

5.  Hydrogel-nanoparticle composites for optically modulated cancer therapeutic delivery.

Authors:  Laura E Strong; Shreyas N Dahotre; Jennifer L West
Journal:  J Control Release       Date:  2014-01-23       Impact factor: 9.776

6.  Co-delivery of doxorubicin and Bcl-2 siRNA by mesoporous silica nanoparticles enhances the efficacy of chemotherapy in multidrug-resistant cancer cells.

Authors:  Alex M Chen; Min Zhang; Dongguang Wei; Dirk Stueber; Oleh Taratula; Tamara Minko; Huixin He
Journal:  Small       Date:  2009-12       Impact factor: 13.281

7.  siRNA-based targeting of antiapoptotic genes can reverse chemoresistance in P-glycoprotein expressing chondrosarcoma cells.

Authors:  Dae Won Kim; Kyung-Ok Kim; Mike J Shin; Jung Hee Ha; Sung Wook Seo; Jay Yang; Francis Y Lee
Journal:  Mol Cancer       Date:  2009-05-15       Impact factor: 27.401

8.  Targeting inhibitor of apoptosis proteins in combination with ErbB antagonists in breast cancer.

Authors:  Fiona M Foster; Thomas W Owens; Jolanta Tanianis-Hughes; Robert B Clarke; Keith Brennan; Nigel J Bundred; Charles H Streuli
Journal:  Breast Cancer Res       Date:  2009-06-29       Impact factor: 6.466

9.  RNAi and cancer: Implications and applications.

Authors:  Maen Abdelrahim; Stephen Safe; Cheryl Baker; Ala Abudayyeh
Journal:  J RNAi Gene Silencing       Date:  2006-02-28

10.  XIAP is not required for human tumor cell survival in the absence of an exogenous death signal.

Authors:  John Sensintaffar; Fiona L Scott; Robert Peach; Jeffrey H Hager
Journal:  BMC Cancer       Date:  2010-01-12       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.